For Drug Toxicity Testing, microRNAs Hold Promise But More Work Remains | GenomeWeb

While much attention has been focused on the use of microRNAs for diagnostic applications, a number of pharmaceutical firms have been exploring the non-coding RNAs' potential as biomarkers of drug-related toxicity.

However, these efforts are early stage and require additional work before miRNAs could reliably replace traditional biomarkers, according to data presented this week at the Cambridge Healthtech Institute microRNA as Biomarkers and Diagnostics meeting in Boston.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.